RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,915,842 | +39.0% | 345,293 | 0.0% | 2.42% | +142.5% |
Q2 2023 | $5,693,882 | -7.6% | 345,293 | 0.0% | 1.00% | -21.5% |
Q1 2023 | $6,160,027 | -38.7% | 345,293 | 0.0% | 1.27% | -41.2% |
Q4 2022 | $10,054,932 | +18.9% | 345,293 | 0.0% | 2.16% | +9.7% |
Q3 2022 | $8,460,000 | +490.4% | 345,293 | 0.0% | 1.97% | +416.5% |
Q2 2022 | $1,433,000 | -64.0% | 345,293 | 0.0% | 0.38% | -61.8% |
Q1 2022 | $3,978,000 | +15.4% | 345,293 | 0.0% | 1.00% | +49.6% |
Q4 2021 | $3,446,000 | -12.1% | 345,293 | +15.0% | 0.67% | +8.8% |
Q3 2021 | $3,922,000 | -33.3% | 300,293 | 0.0% | 0.62% | -15.3% |
Q2 2021 | $5,880,000 | +37.5% | 300,293 | +49.4% | 0.73% | -8.0% |
Q1 2021 | $4,276,000 | -28.5% | 201,046 | 0.0% | 0.79% | +31.3% |
Q4 2020 | $5,977,000 | +17.4% | 201,046 | -14.4% | 0.60% | -57.6% |
Q3 2020 | $5,089,000 | -17.4% | 234,846 | -15.0% | 1.42% | -28.4% |
Q2 2020 | $6,161,000 | +46.5% | 276,289 | 0.0% | 1.98% | -18.1% |
Q1 2020 | $4,205,000 | – | 276,289 | – | 2.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |